|drug663||Imatinib tablets Wiki||1.00|
|drug166||Baricitinib Oral Tablet Wiki||0.71|
There is one clinical trial.
In absence of vaccine and medications specifically designed to treat SARS-CoV-2 disease, identifying treatment options is critical at this time to control the disease outbreak. For this, we have designed a phase II trial of efficacy and safety with 3 branches of different combinations of treatment to identify which is the best early treatment option for patients with pneumonia due to SARS-CoV-2 (Covid-19) Identifying treatment options as early as possible is critical to the SARS-CoV-2 outbreak response. Currently, there is no approved vaccine for the disease and the treatments being used are not specifically designed for the SARS-CoV-2 virus, but are different groups of drugs used for other pathologies with mechanisms of action that justify their use because they inhibit entry of the virus into virus cells or proteases. The study aims to compare lopinavir / ritonavir (200 /50), imatinib 400mg, baricitinib 4mg, in combination with hydroxychloroquine 200mg, administered for 7 days in the setting of SARS-CoV-2 pneumonia treatment. Patients who meet inclusion criteria and do not have any exclusion criteria will be randomized to receive open treatment 1:1:1
Description: time from inclusion to improvement by 2 points on the "seven-category ordinal scale" or high, whichever comes firstMeasure: time to clinical improvement Time: baseline to day 14
Description: number of serious adverse effects and premature discontinuation of treatmentMeasure: Safety of treatments Time: through study completion, an average of 1 month
Description: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0Measure: Tolerability of treatments Time: during treatment and up to 30 days after the last treatment dose
Description: Possible biomarkers and genetic markers of susceptibility to SARS-CoV-2 using high-performance techniques with serum DNA from the participantsMeasure: Biomarkers and genetic markers of susceptibility to SARS-CoV-2 Time: baseline